Abstract
Objective:Serous carcinoma and clear cell carcinomas account for 10% and 3% of endometrial cancers but are responsible for 39% and 8% of cancer deaths, respectively. In this study, we aimed to compare serous carcinoma and clear cell carcinoma regarding the surgico-pathologic and clinical characteristics, and survival, and to detect factors that affected recurrence and survival.Materials and Methods:We retrospectively analyzed patients with clear cell and serous endometrial cancer who underwent surgery between January 1993 and December 2013 in our clinic. We used Kaplan-Meier estimator to analyze survival.Results:The tumor type in 49 patients was clear cell carcinomas and was serous uterine carcinoma in 51 patients. Advanced stage (stage III and IV) disease was present in 42% of the patients in the clear cell group, whereas this rate was 62% in the serous group (p=0.044). Lymph node metastasis was detected in 37% of the patients with clear cell carcinomas and 51% of the patients with serous carcinoma (p=0.17). The adjuvant therapies used did not differ significantly between the groups (p=0.192). The groups had similar recurrence patterns. Five-year progression-free survival and the 5-year overall survival were 60.6% and 85.8%, 45.5% and 67.8% in the patients with clear cell carcinomas and serous tumor, respectively.Conclusion:With the exception that more advanced stages were observed in patients with serous carcinoma endometrial cancers at presentation, the surgico-pathologic features, recurrence rates and patterns, and survival rates did not differ significantly between the groups with clear cell carcinoma and serous carcinoma endometrial cancers.
Highlights
Endometrial cancer (EC) is the sixth most common cancer in women worldwide and the twelfth most common cancer overall[1]
We aimed to present a comparison of serous carcinoma (SC) and cell carcinoma (CCC) in terms of surgico-pathologic and clinical features, and survival, and to determine factors that affect recurrence and survival
There was no difference between the 2 tumor types in terms of number of harvested lymph nodes, myometrial invasion, cervical involvement, cytologic positivity, tumor size, ovarian involvement, omental metastasis, preoperative cancer antigen-125 (Ca)-125 level, and the site of recurrence (Table 1)
Summary
Endometrial cancer (EC) is the sixth most common cancer in women worldwide and the twelfth most common cancer overall[1]. It is important to approach these tumors differently and to separate them from endometrioid tumors in studies that analyze patients with ECs. it is important to approach these tumors differently and to separate them from endometrioid tumors in studies that analyze patients with ECs They are usually analyzed together in studies that investigate characteristic features, management, and survival of patients with these tumors they are rare are more aggressive than endometrioid ECs. They are usually analyzed together in studies that investigate characteristic features, management, and survival of patients with these tumors they are rare are more aggressive than endometrioid ECs This may explain the disparate results obtained in the literature, because these two tumors are different with distinct clinical behavior and pathogenetic properties. They have different molecular alterations and separate ways of spreading. Many studies have compared these tumors with type I or poorly-differentiated ECs. there is little data in the literature with regard to the differences between these 2 tumors. We aimed to present a comparison of SC and CCC in terms of surgico-pathologic and clinical features, and survival, and to determine factors that affect recurrence and survival
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
